Cargando…
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
Ovarian cancer (OC) is the most lethal gynecologic malignancy, affecting approximately 1 in 70 women with only 45% surviving 5 years after diagnosis. This disease typically presents at an advanced stage, and optimal debulking with platinum-based chemotherapy remains the cornerstone of management. Al...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710491/ https://www.ncbi.nlm.nih.gov/pubmed/34966689 http://dx.doi.org/10.3389/fonc.2021.795547 |
_version_ | 1784623165963501568 |
---|---|
author | Chardin, Laure Leary, Alexandra |
author_facet | Chardin, Laure Leary, Alexandra |
author_sort | Chardin, Laure |
collection | PubMed |
description | Ovarian cancer (OC) is the most lethal gynecologic malignancy, affecting approximately 1 in 70 women with only 45% surviving 5 years after diagnosis. This disease typically presents at an advanced stage, and optimal debulking with platinum-based chemotherapy remains the cornerstone of management. Although most ovarian cancer patients will respond effectively to current management, 70% of them will eventually develop recurrence and novel therapeutic strategies are needed. There is a rationale for immune-oncological treatments (IO) in the managements of patients with OC. Many OC tumors demonstrate tumor infiltrating lymphocytes (TILs) and the degree of TIL infiltration is strongly and reproducibly correlated with survival. Unfortunately, results to date have been disappointing in relapsed OC. Trials have reported very modest single activity with various antibodies targeting PD-1 or PD-L1 resulting in response rate ranging from 4% to 15%. This may be due to the highly immunosuppressive TME of the disease, a low tumor mutational burden and low PD-L1 expression. There is an urgent need to improve our understanding of the immune microenvironment in OC in order to develop effective therapies. This review will discuss immune subpopulations in OC microenvironment, current immunotherapy modalities targeting these immune subsets and data from clinical trials testing IO treatments in OC and its combination with other therapeutic agents. |
format | Online Article Text |
id | pubmed-8710491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87104912021-12-28 Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 Chardin, Laure Leary, Alexandra Front Oncol Oncology Ovarian cancer (OC) is the most lethal gynecologic malignancy, affecting approximately 1 in 70 women with only 45% surviving 5 years after diagnosis. This disease typically presents at an advanced stage, and optimal debulking with platinum-based chemotherapy remains the cornerstone of management. Although most ovarian cancer patients will respond effectively to current management, 70% of them will eventually develop recurrence and novel therapeutic strategies are needed. There is a rationale for immune-oncological treatments (IO) in the managements of patients with OC. Many OC tumors demonstrate tumor infiltrating lymphocytes (TILs) and the degree of TIL infiltration is strongly and reproducibly correlated with survival. Unfortunately, results to date have been disappointing in relapsed OC. Trials have reported very modest single activity with various antibodies targeting PD-1 or PD-L1 resulting in response rate ranging from 4% to 15%. This may be due to the highly immunosuppressive TME of the disease, a low tumor mutational burden and low PD-L1 expression. There is an urgent need to improve our understanding of the immune microenvironment in OC in order to develop effective therapies. This review will discuss immune subpopulations in OC microenvironment, current immunotherapy modalities targeting these immune subsets and data from clinical trials testing IO treatments in OC and its combination with other therapeutic agents. Frontiers Media S.A. 2021-12-13 /pmc/articles/PMC8710491/ /pubmed/34966689 http://dx.doi.org/10.3389/fonc.2021.795547 Text en Copyright © 2021 Chardin and Leary https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chardin, Laure Leary, Alexandra Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title | Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title_full | Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title_fullStr | Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title_full_unstemmed | Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title_short | Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1 |
title_sort | immunotherapy in ovarian cancer: thinking beyond pd-1/pd-l1 |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710491/ https://www.ncbi.nlm.nih.gov/pubmed/34966689 http://dx.doi.org/10.3389/fonc.2021.795547 |
work_keys_str_mv | AT chardinlaure immunotherapyinovariancancerthinkingbeyondpd1pdl1 AT learyalexandra immunotherapyinovariancancerthinkingbeyondpd1pdl1 |